Solventum (SOLV) cash flow statement

Health Care Technology · NYSE · Health Care

$86.06 -2.92% Close Nov 17, 2026 Live

TrendArc score 34 of 100 · Health 3.5 · Momentum 5.8 · Moat 5.3 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

-$10 million

against $805 million the year before

In the fiscal year to December 2025, Solventum's capital spending of $379 million exceeded its cash from operations of $369 million, a free cash flow of -$10 million. That was -0.1% of revenue, against 9.8% the year before. Over the last four quarters, to September 30, 2026, it was $0.

Free cash flow and net income, the last 5 fiscal years

-$500M$500M$1.00B$1.50B$2.00B20212022202320242025$1.93BFree cash flow -$10.0MNet income $1.56B-$500M$500M$1.00B$1.50B$2.00B202120232025Free cash flow -$10.0MNet income $1.56B

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 0.37
  2. Capital spending -0.38
  3. Free cash flow -0.01
  4. Businesses bought and sold, net 3.19
  5. Debt and other -3.07
  6. Net change in cash 0.12

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 5 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Operating activities
Net income1.560.481.351.341.46
Depreciation and amortisation0.490.560.560.580.60
Stock-based pay0.170.160.110.040.040.04
Working capital and other items-1.840.04-0.03-0.280.11
Cash from operations0.310.371.191.921.682.20
Investing activities
Capital spending-0.31-0.38-0.38-0.29-0.25-0.28
Businesses bought and sold, net3.190.000.060.000.00
Investments bought and sold, net0.000.000.000.000.00
Cash from investing2.80-0.38-0.23-0.25-0.28
Financing activities
Debt issued or repaid, net-3.078.000.000.000.00
Shares issued less bought back-0.400.000.000.000.000.00
Dividends paid0.000.000.000.000.000.00
Other financing0.01-8.24-1.55-1.46-1.96
Cash from financing-3.06-0.24-1.55-1.46-1.96
Net change in cash0.120.570.13-0.03-0.03
Free cash flow
Free cash flow0.00-0.010.811.631.431.93
Free cash flow margin0.0%-0.1%9.8%19.8%17.6%23.6%
Free cash flow per share-$0.06$4.63$9.41$8.27—

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Solventum against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
Veeva SystemsVEEV Jan 2026$1.39B43.4%
Quest DiagnosticsDGX Dec 2025$1.36B12.3%
DaVitaDVA Dec 2025$1.31B9.6%
LabcorpLH Dec 2025$1.21B8.6%
Universal Health ServicesUHS Dec 2025$825M4.7%
Henry ScheinHSIC Dec 2025$521M4.0%
Hims & Hers HealthHIMS Dec 2025$57.4M2.4%
CenteneCNC Dec 2025$4.32B2.2%
SolventumSOLV Dec 2025-$10.0M-0.1%
Peer median6.7%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Solventum with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Solventum from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.